It is the overall goal of this research is to elucidate the mechanisms that underlie the development of resistance to cisplatin (DDP) and the multi-drug resistant phenotype that accompanies it. This project continues to focus on the role that loss of DNA mismatch repair (MMR) and its associated genomic instability plays in the development of resistance to this important drug. DDP is a mutagen, and we have demonstrated that even a single exposure of human cells to the drug is sufficient to generate clones in the surviving population that are highly resistant to many classes of chemotherapeutic agents. We found that many of the mutations induced by DDP are attributable to errors made by pol zeta during synthesis across DDP adducts in DNA. We have also discovered that DDP produces an error-prone state (EPS) in which DNA sequences not containing adducts are at increased risk of mutation as well. It is our hypothesis that DDP-induced genomic instability plays a central role in the development of the multidrug-resistant phenotype that accompanies emergence of resistance to DDP, and that this is augmented by defects in pathways that normally protect against genomic instability many of which are often disabled in tumor cells.
The specific aims are directed at the following questions: 1) What is the mechanism by which loss of MMR renders cells hypersensitive to the mutagenic effect of DDP? 2) What is the mechanism by which DDP causes mutations in DNA sequences not containing DDP adducts? 3) How important is DDP-induced mutagenesis relative to selection of pre-existing variants in the development of resistance? This project focuses on genomic instability produced by DDP. However, we have already demonstrated that oxidative stress and severe hypoxia both produce similar types of genomic instability in human cells. Thus, it is very likely that the mechanisms underlying the DDP-induced mutagenicity will be of fundamental importance to understanding the genomic instability produced by many types of cellular injury.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078648-06
Application #
6623829
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolpert, Mary K
Project Start
1998-07-01
Project End
2006-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
6
Fiscal Year
2003
Total Cost
$295,197
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Larson, Christopher A; Blair, Brian G; Safaei, Roohangiz et al. (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-30
Lin, Xinjian; Okuda, Tsuyoshi; Trang, Julie et al. (2006) Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 69:1748-54
Cheng, Timothy C; Manorek, Gerald; Samimi, Goli et al. (2006) Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58:384-95
Lin, Xinjian; Trang, Julie; Okuda, Tsuyoshi et al. (2006) DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res 12:563-8
Okuda, Tsuyoshi; Lin, Xinjian; Trang, Julie et al. (2005) Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol 67:1852-60
Safaei, Roohangiz; Katano, Kuniyuki; Larson, Barrett J et al. (2005) Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 11:756-67
Samimi, Goli; Manorek, Gerald; Castel, Rob et al. (2005) cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 55:1-11
Katano, Kuniyuki; Safaei, Roohangiz; Samimi, Goli et al. (2004) Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 10:4578-88
Wu, Fang; Lin, Xinjian; Okuda, Tsuyoshi et al. (2004) DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res 64:8029-35
Samimi, Goli; Varki, Nissi M; Wilczynski, Sharon et al. (2003) Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 9:5853-9

Showing the most recent 10 out of 23 publications